Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Fizza Arain, Lars Gullestad, Ståle Nymo, John Kjekshus, John G. Cleland, Annika Michelsen, John J. McMurray, John Wikstrand, Pål Aukrust & Thor Ueland. (2017) Low YKL-40 in chronic heart failure may predict beneficial effects of statins: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA). Biomarkers 22:3-4, pages 261-267.
Read now
Read now
A. D. Kjaergaard, J. S. Johansen, S. E. Bojesen & B. G. Nordestgaard. (2016) Role of inflammatory marker YKL-40 in the diagnosis, prognosis and cause of cardiovascular and liver diseases. Critical Reviews in Clinical Laboratory Sciences 53:6, pages 396-408.
Read now
Read now
Anders B. Mathiasen, Marina J. Harutyunyan, Erik Jørgensen, Steffen Helqvist, Rasmus Ripa, Jens P. Gøtze, Julia S. Johansen & Jens Kastrup. (2011) Plasma YKL-40 in relation to the degree of coronary artery disease in patients with stable ischemic heart disease. Scandinavian Journal of Clinical and Laboratory Investigation 71:5, pages 439-447.
Read now
Read now
Articles from other publishers (25)
Zhuo Li, Fangnan Wu, Lei Xi & Zhenjun Tian. (2022) Role of Chitinase-3-like Protein 1 in Cardioprotection and Angiogenesis by Post-Infarction Exercise Training. Biomedicines 10:5, pages 1028.
Crossref
Crossref
Ummugulsum Can. 2022. Biomarkers in Nutrition. Biomarkers in Nutrition
767
785
.
Ummugulsum Can. 2022. Biomarkers in Nutrition. Biomarkers in Nutrition
1
20
.
Marcus Hjort, Kai M. Eggers, Lars Lindhagen, Tomasz Baron, David Erlinge, Tomas Jernberg, György Marko-Varga, Melinda Rezeli, Jonas Spaak & Bertil Lindahl. (2021) Differences in biomarker concentrations and predictions of long-term outcome in patients with ST-elevation and non-ST-elevation myocardial infarction. Clinical Biochemistry 98, pages 17-23.
Crossref
Crossref
Yingjian Deng, Guiyang Li, Dong Chang & Xin Su. (2020) YKL-40 as a novel biomarker in cardio-metabolic disorders and inflammatory diseases. Clinica Chimica Acta 511, pages 40-46.
Crossref
Crossref
Jakob Schroder, Janus Christian Jakobsen, Per Winkel, Jørgen Hilden, Gorm Boje Jensen, Ahmad Sajadieh, Anders Larsson, Johan Ärnlöv, Marina Harutyunyan, Julia S. Johansen, Erik Kjøller, Christian Gluud & Jens Kastrup. (2020) Prognosis and Reclassification by YKL‐40 in Stable Coronary Artery Disease. Journal of the American Heart Association 9:5.
Crossref
Crossref
Luyu Yang, Hui Dong, Huizhi Lu, Youxia Liao, Hao Zhang, Lingwen Xu, Yun Tan, Song Cao, Jinhui Tan & Shouzhi Fu. (2019) Serum YKL-40 predicts long-term outcome in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Medicine 98:12, pages e14920.
Crossref
Crossref
Yuanfei Tan, Xiaoying Ji, Zhifeng Mo & Yaoliang Zhou. (2019) Serum YKL-40 positively correlates with MMP-9 and CRP in patients with acute ST segment elevation myocardial infarction following emergency treatment. Medicine 98:47, pages e17950.
Crossref
Crossref
Selcuk Pala, Munevver Sari, Gokhan Kahveci, Elnur Alizade, Ugur Arslantas & Abdulkadir Uslu. (2018) Plasma YKL-40 Elevation on Admission and Follow-Up Is Associated with Diastolic Dysfunction and Mortality in Patients with Acute Myocardial Infarction. Cardiology Research and Practice 2018, pages 1-7.
Crossref
Crossref
Christoffer Stark, Mikko Helenius, Pekka Taimen, Rasmus Kentala, Antti Saraste, Tero-Pekka Alastalo, Timo Savunen & Juha Koskenvuo. (2016) Thymosin beta 4 treatment improves left ventricular function after myocardial infarction and is related to Up-regulation of chitinase 3-like-1 in mice. Translational Medicine Communications 1:1.
Crossref
Crossref
Doaa S. E. Zaky, Fatma M. Mabrouk, Eman R. Zaki & Olfat M. Hendy. (2016) The value of YKL-40 in ischemic heart disease patients. The Egyptian Journal of Internal Medicine 28:2, pages 71-77.
Crossref
Crossref
Naja Dam Mygind, Anna Axelsson, Martin H. Ruwald, Morten Dalsgaard, Rolf Steffensen, Kasper Iversen, Julia S. Johansen & Jens Kastrup. (2016) The inflammatory biomarker YKL-40 decreases stepwise after exercise stress test. Cardiovascular Endocrinology 5:1, pages 21-27.
Crossref
Crossref
Naja Dam Mygind & Jens Kastrup. 2015. General Methods in Biomarker Research and their Applications. General Methods in Biomarker Research and their Applications
783
810
.
Marina Harutyunyan, Julia S Johansen, Naja D Mygind, Simon B Reuter & Jens Kastrup. (2014) Serum YKL-40 for monitoring myocardial ischemia after revascularization in patients with stable coronary artery disease. Biomarkers in Medicine 8:8, pages 977-988.
Crossref
Crossref
Naja Dam Mygind & Jens Kastrup. 2014. General Methods in Biomarker Research and their Applications. General Methods in Biomarker Research and their Applications
1
22
.
M. Çetin, S.A. Kocaman, A. Çanga, A. Kırbaş, A. Yılmaz, T. Erdoğan, Ö Akgül, Y. Uğurlu & M.E. Durakoğlugil. (2012) Elevated serum YKL-40 level predicts myocardial reperfusion and in-hospital MACE in patients with STEMIVoraussage myokardialer Reperfusion und schwerer kardialer Ereignisse durch erhöhten YKL-40-Serumspiegel bei stationären Patienten mit STEMI. Herz 38:2, pages 202-209.
Crossref
Crossref
N. D. Mygind, K. Iversen, L. Køber, J. P. Goetze, H. Nielsen, S. Boesgaard, M. Bay, J. S. Johansen, O. W. Nielsen, V. Kirk & J. Kastrup. (2012)
The inflammatory biomarker
YKL
‐40 at admission is a strong predictor of overall mortality
. Journal of Internal Medicine 273:2, pages 205-216.
Crossref
Crossref
Stine Brinkløv Thomsen, Camilla Noelle Rathcke, Nils Bruun Jørgensen, Sten Madsbad & Henrik Vestergaard. (2013) Effects of Roux-en-Y Gastric Bypass on Fasting and Postprandial Levels of the Inflammatory Markers YKL-40 and MCP-1 in Patients with Type 2 Diabetes and Glucose Tolerant Subjects. Journal of Obesity 2013, pages 1-10.
Crossref
Crossref
Marina Harutyunyan, Michael Christiansen, Julia S. Johansen, Lars Køber, Christian Torp-Petersen & Jens Kastrup. (2012) The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart failure. Immunobiology 217:6, pages 652-656.
Crossref
Crossref
Jens Kastrup. (2012) Can YKL-40 be a new inflammatory biomarker in cardiovascular disease?. Immunobiology 217:5, pages 483-491.
Crossref
Crossref
Anne Mette Mørup, Brian Kornblit, Julia S. Johansen, Tania Nicole Masmas, Hans O. Madsen, Lars Vindeløv & Peter Garred. (2011) The Prognostic Value of YKL-40 Concentrations in Nonmyeloablative Conditioning Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation 17:9, pages 1299-1307.
Crossref
Crossref
Naja Dam Mygind, Marina J. Harutyunyan, Anders Bruun Mathiasen, Rasmus S. Ripa, Jens Jacob Thune, Jens Peter Gøtze, Julia S. Johansen & Jens Kastrup. (2010) The influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease. Inflammation Research 60:3, pages 281-287.
Crossref
Crossref
Anna Meiliana & Andi Wijaya. (2010) Novel Biomarkers in Cardiovascular Disease: A Review. The Indonesian Biomedical Journal 2:3, pages 66.
Crossref
Crossref
Anders Bruun MathiasenKristoffer Mads Aaris HenningsenMarina Jurjevna HarutyunyanNaja Dam MygindJens Kastrup. (2010) YKL-40: a new biomarker in cardiovascular disease?. Biomarkers in Medicine 4:4, pages 591-600.
Crossref
Crossref
Nicolai A. Schultz & Julia S. Johansen. (2010) YKL-40—A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients?. Cancers 2:3, pages 1453-1491.
Crossref
Crossref